SCHEMBL2181670

SCHEMBL2181670

N#CC(C#N)=Cc1cn(C(c2ccccc2)c2ccccc2)c(=O)[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.53
MET P08581 7/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
TRPA1 O75762 1/20 0.37
SNCA P37840 2/20 0.36
APP P05067 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
DAO P14920 1/20 0.34
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TK1 P04183 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12410791 0.84 GAA (0.48) GAAMETDAO
SCHEMBL12410771 0.84 GAA (0.62) GAAMETMEN1KMT2AALDH1A1
SCHEMBL1558602 0.81 GAA (0.55) GAAMETMEN1KMT2ADAO
SCHEMBL17243372 0.81 GAA (0.58) GAAMETMEN1KMT2AALDH1A1
SCHEMBL1558603 0.81 GAA (0.55) GAAMETMEN1KMT2ADAO
SCHEMBL12410795 0.77 GAA (0.64) GAAMETMEN1KMT2ACYP1A2
SCHEMBL17243356 0.76 GAA (0.58) GAAMETMEN1KMT2ADAO
SCHEMBL12499643 0.76 GAA (0.58) GAAMETMEN1KMT2ADAO
SCHEMBL17243371 0.75 GAA (0.55) GAAMETMEN1KMT2ADAO
SCHEMBL12495880 0.74 GAA (0.56) GAAMETMEN1KMT2ADAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-9181199-B2 Uracil derivatives and use thereof RESPROTECT GMBH (DE) 2015-11-10 US disclosed
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2011-07-07 US disclosed
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF RESPROTECT GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166096-A1 URACIL DERIVATIVES AND USE THEREOF TYMP, UNG, DPYD GAA 2007/4885MET 4164/4885MEN1 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.